DNLI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.764

+14.07%

-0.772

-1.03%

-0.602

-16.39%

Estimates Revision

The market is revising Downward the revenue expectations for Denali Therapeutics Inc. (DNLI) for FY2025, with the revenue forecasts being adjusted by -53.01% over the past three months. During the same period, the stock price has changed by 30.77%.

Revenue Estimates for FY2025

Revise Downward

-53.01%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.27%

In Past 3 Month

Stock Price

Go Up

+30.77%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast DNLI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DNLI is 31.14 USD with a low forecast of 26.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 17.340

Low

26.00

Averages

31.14

High

37.00

Current: 17.340

Low

26.00

Averages

31.14

High

37.00

Wedbush

Laura Chico

Outperform

downgrade

$31 -> $30

2025-12-11

New

Reason

Wedbush

Laura Chico

Price Target

$31 -> $30

2025-12-11

New

downgrade

Outperform

Reason

Wedbush analyst Laura Chico lowered the firm's price target on Denali Therapeutics to $30 from $31 and keeps an Outperform rating on the shares. The firm notes the company completed a $200M secondary offering this week. The deal included issuance of 9.1M shares of common stock at $17.50/share, and pre-funded warrants to purchase an additional 2.3M shares of common stock. The deal also included an overallotment of 1.7M additional shares. Assuming exercise of the shoe, Wedbush estimate the offering will generate $217M in net proceeds. Its prior estimates did not incorporate a near-term financing. However, with the negotiations continuing with FDA around a potential tivi PRV issuance, the raise makes sense, the firm argues.

Wedbush

Laura Chico

Outperform

maintain

$30 -> $31

2025-12-05

Reason

Wedbush

Laura Chico

Price Target

$30 -> $31

2025-12-05

maintain

Outperform

Reason

Wedbush analyst Laura Chico raised the firm's price target on Denali Therapeutics to $31 from $30 and keeps an Outperform rating on the shares. The firm says most notable in the Denali Investor Day event, management indicated the tivi review remains ongoing with its late-cycle meeting wrapped, and key commercial hires are already made. No changes were made to Wedbush's tivi revenue estimates, which continues to assume modest revenue in 2026 and increasing to $433M by FY30.

BofA

Buy

maintain

$26 -> $29

2025-12-05

Reason

BofA

Price Target

$26 -> $29

2025-12-05

maintain

Buy

Reason

BofA raised the firm's price target on Denali Therapeutics to $29 from $26 and keeps a Buy rating on the shares after the company hosted an investor day to outline its three-year growth strategy. Following the event, the firm introduced the royalty agreement with Royalty Pharma into its model and adjusted its cost of goods sold estimates based on management commentary, while also increasing its gross pipeline value to $4.5B from $4B.

BofA

Buy

maintain

$27 -> $26

2025-11-17

Reason

BofA

Price Target

$27 -> $26

2025-11-17

maintain

Buy

Reason

BofA lowered the firm's price target on Denali Therapeutics to $26 from $27 and keeps a Buy rating on the shares. The firm made changes to its model following the company's Q3 update, noting that Denali management highlighted that they continue to engage with the FDA on the ongoing biologics license application review of tividefusp alfa for Hunter syndrome following the recent extension with new target action date of April 5, 2026.

BofA

Tazeen Ahmad

Buy

downgrade

$27 -> $26

2025-11-16

Reason

BofA

Tazeen Ahmad

Price Target

$27 -> $26

2025-11-16

downgrade

Buy

Reason

BofA analyst Tazeen Ahmad lowered the firm's price target on Denali Therapeutics to $26 from $27 and keeps a Buy rating on the shares. The firm updated smid-cap biotech models following the Q3 reports.

BofA

Tazeen Ahmad

Buy

downgrade

$28 -> $27

2025-05-19

Reason

BofA

Tazeen Ahmad

Price Target

$28 -> $27

2025-05-19

downgrade

Buy

Reason

BofA analyst Tazeen Ahmad lowered the firm's price target on Denali Therapeutics to $27 from $28 and keeps a Buy rating on the shares. Denali announced they have completed the biologics license application for tividenofusp alfa for Hunter Syndrome and noted the application was submitted under the accelerated approval path, the analyst tells investors. The firm updated its model for Q1 results, cash and share count and increase op expense estimates in line with trend and slightly pushed its near-term estimates for tivi' as it expects a launch in early 2026, the analyst noted.

Valuation Metrics

The current forward P/E ratio for Denali Therapeutics Inc (DNLI.O) is -6.09, compared to its 5-year average forward P/E of -13.48. For a more detailed relative valuation and DCF analysis to assess Denali Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-13.48

Current PE

-6.09

Overvalued PE

-3.60

Undervalued PE

-23.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.22

Current EV/EBITDA

-3.31

Overvalued EV/EBITDA

-1.60

Undervalued EV/EBITDA

-18.83

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

71.83

Current PS

207.14

Overvalued PS

118.98

Undervalued PS

24.68

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

DNLI News & Events

Events Timeline

No data

News

8.5

12-10Newsfilter

Denali Therapeutics Prices Public Offering at $200 Million

8.5

12-10Globenewswire

Denali Therapeutics Prices Public Offering at $17.50 per Share, Raising $200 Million

8.5

12-10Yahoo Finance

Denali Therapeutics Reveals Pricing for Public Offering of Common Stock and Pre-Funded Warrants

People Also Watch

Frequently Asked Questions

What is Denali Therapeutics Inc (DNLI) stock price today?

The current price of DNLI is 17.34 USD — it has decreased -3.56 % in the last trading day.

What is Denali Therapeutics Inc (DNLI)'s business?

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

What is the price predicton of DNLI Stock?

What is Denali Therapeutics Inc (DNLI)'s revenue for the last quarter?

Denali Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

What is Denali Therapeutics Inc (DNLI)'s earnings per share (EPS) for the last quarter?

Denali Therapeutics Inc. EPS for the last quarter amounts to -0.74 USD, increased 17.46 % YoY.

What changes have occurred in the market's expectations for Denali Therapeutics Inc (DNLI)'s fundamentals?

How many employees does Denali Therapeutics Inc (DNLI). have?

Denali Therapeutics Inc (DNLI) has 422 emplpoyees as of December 16 2025.

What is Denali Therapeutics Inc (DNLI) market cap?

Today DNLI has the market capitalization of 2.71B USD.